JP2012144538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012144538A5 JP2012144538A5 JP2012040759A JP2012040759A JP2012144538A5 JP 2012144538 A5 JP2012144538 A5 JP 2012144538A5 JP 2012040759 A JP2012040759 A JP 2012040759A JP 2012040759 A JP2012040759 A JP 2012040759A JP 2012144538 A5 JP2012144538 A5 JP 2012144538A5
- Authority
- JP
- Japan
- Prior art keywords
- chemotherapeutic agent
- tumor
- antagonist
- coded
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58074504P | 2004-06-18 | 2004-06-18 | |
| US60/580,745 | 2004-06-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516758A Division JP5039544B2 (ja) | 2004-06-18 | 2005-06-17 | 腫瘍の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012144538A JP2012144538A (ja) | 2012-08-02 |
| JP2012144538A5 true JP2012144538A5 (OSRAM) | 2013-05-09 |
| JP5719322B2 JP5719322B2 (ja) | 2015-05-13 |
Family
ID=35351719
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516758A Expired - Lifetime JP5039544B2 (ja) | 2004-06-18 | 2005-06-17 | 腫瘍の治療 |
| JP2012040759A Expired - Lifetime JP5719322B2 (ja) | 2004-06-18 | 2012-02-27 | 腫瘍の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516758A Expired - Lifetime JP5039544B2 (ja) | 2004-06-18 | 2005-06-17 | 腫瘍の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8147827B2 (OSRAM) |
| EP (1) | EP1786466B1 (OSRAM) |
| JP (2) | JP5039544B2 (OSRAM) |
| AU (1) | AU2005265067B2 (OSRAM) |
| CA (1) | CA2570887C (OSRAM) |
| ES (1) | ES2429041T3 (OSRAM) |
| WO (1) | WO2006009805A2 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6998255B1 (en) * | 1999-09-24 | 2006-02-14 | Solvay Pharmaceuticals B.V. | Human G-protein coupled receptor |
| CA2618542A1 (en) * | 2005-08-09 | 2007-02-15 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| AU2006294663B2 (en) * | 2005-09-26 | 2012-03-22 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
| EP2338488A1 (en) * | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| US8535677B2 (en) | 2006-06-06 | 2013-09-17 | Oxford Biotherapeutics, Ltd. | Antibody drug conjugate treatment of colorectal cancer |
| US20080124329A1 (en) * | 2006-07-05 | 2008-05-29 | Schreiner George F | Conditioned Cell Immunization |
| IN2009KN02404A (OSRAM) * | 2006-12-14 | 2015-08-07 | Medarex Inc | |
| EP2093567A1 (en) * | 2008-02-21 | 2009-08-26 | Pangaea Biotech, S.A. | Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy |
| WO2009147781A1 (ja) * | 2008-06-02 | 2009-12-10 | 国立大学法人東京大学 | 抗がん剤 |
| WO2009147695A1 (ja) * | 2008-06-02 | 2009-12-10 | 国立大学法人東京大学 | 抗がん剤 |
| JP4686733B2 (ja) * | 2008-06-02 | 2011-05-25 | 国立大学法人 東京大学 | 抗がん剤 |
| JP2011074093A (ja) * | 2008-06-02 | 2011-04-14 | Univ Of Tokyo | 抗がん剤 |
| SG10201401604VA (en) | 2009-04-20 | 2014-08-28 | Oxford Biotherapeutics Ltd | Antibodies Specific To Cadherin-17 |
| US20140086939A1 (en) * | 2011-02-28 | 2014-03-27 | Michael Karin | Compositions and methods for detecting and treating cancer |
| JP5771123B2 (ja) * | 2011-11-09 | 2015-08-26 | 株式会社 資生堂 | プロフィラグリンｃ末端ドメイン特異的抗体及びその用途 |
| JP2013235003A (ja) * | 2012-05-10 | 2013-11-21 | Fujita Gakuen | 細胞におけるｄｎａ損傷の検出方法及びｄｎａ鎖切断応答性細胞表面抗原に対する抗体 |
| GB201213652D0 (en) * | 2012-08-01 | 2012-09-12 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| CA2909642A1 (en) * | 2013-04-15 | 2014-10-23 | Regeneron Pharmaceuticals, Inc. | Markers of tumor cell response to anti-cancer therapy |
| KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
| KR102387565B1 (ko) * | 2018-11-20 | 2022-04-18 | (주)엠디바이오랩 | 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6831057B2 (en) | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
| CA2375189C (en) * | 1999-05-28 | 2010-02-09 | The Government Of The United States Of America | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| EP1206234A4 (en) * | 1999-06-03 | 2005-06-01 | Jessie L S Au | METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH |
| US6652853B2 (en) | 2001-03-08 | 2003-11-25 | Ludwig Institute For Cancer Research | Method for treating cancer using A33 specific antibodies and chemotherapeutic agents |
| US20050032724A1 (en) * | 2001-07-23 | 2005-02-10 | Gunther Heinrich | Methods for improved treatment of cancer with irinotecan based on mrp1 |
| EP1617849B1 (en) * | 2003-04-07 | 2008-06-18 | Prospect Therapeutics, Inc. | Composition and uses of galectin antagonists |
-
2005
- 2005-06-17 WO PCT/US2005/021378 patent/WO2006009805A2/en not_active Ceased
- 2005-06-17 ES ES05789195T patent/ES2429041T3/es not_active Expired - Lifetime
- 2005-06-17 US US11/155,987 patent/US8147827B2/en active Active
- 2005-06-17 EP EP05789195.4A patent/EP1786466B1/en not_active Expired - Lifetime
- 2005-06-17 CA CA2570887A patent/CA2570887C/en not_active Expired - Lifetime
- 2005-06-17 JP JP2007516758A patent/JP5039544B2/ja not_active Expired - Lifetime
- 2005-06-17 AU AU2005265067A patent/AU2005265067B2/en not_active Expired
-
2012
- 2012-02-27 JP JP2012040759A patent/JP5719322B2/ja not_active Expired - Lifetime
- 2012-03-06 US US13/413,276 patent/US20120201822A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012144538A5 (OSRAM) | ||
| HUE049171T2 (hu) | Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek | |
| JP2012140442A5 (OSRAM) | ||
| EP3043819A4 (en) | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis | |
| BR112014016889A8 (pt) | composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8 | |
| PL2612551T5 (pl) | Kompozycja roztoczy zawierająca roztocza drapieżnego i unieruchomiony żer w kontakcie ze środkiem ograniczającym grzyby oraz sposoby i zastosowania dotyczące stosowania wspomnianej kompozycji | |
| JP2014530840A5 (OSRAM) | ||
| SI2900279T1 (sl) | GRPR-antagonisti za detekcijo, diagnozo in zdravljenje GRPR-pozitivnega raka | |
| EP2858378A4 (en) | ULTRASONIC ECHOLOT CONVERTER AND ULTRASONIC FLOWMETER THEREWITH | |
| IL228771A0 (en) | Glycoside derivatives and their uses for the treatment of diabetes | |
| Casals et al. | Next-generation sequencing approaches for genetic mapping of complex diseases | |
| WO2013188605A3 (en) | Predictive markers for cancer and metabolic syndrome | |
| JP2015518492A5 (OSRAM) | ||
| GB201511770D0 (en) | Novel pharmaceutical formulationsand their use in the treatment of periodontal disease | |
| JP2014507563A5 (OSRAM) | ||
| JP2012101354A5 (OSRAM) | ||
| JP2010281322A5 (OSRAM) | ||
| IL233875A0 (en) | A preparation and its use for the treatment of anal fissures | |
| JP2012179231A5 (OSRAM) | ||
| CL2014003484A1 (es) | Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica. | |
| JP2014529579A5 (OSRAM) | ||
| HK1206985A1 (en) | Combination therapy of anti-mif antibodies and chemotherapeutics | |
| JP2013059750A5 (OSRAM) | ||
| PL3027208T3 (pl) | Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystych | |
| JP2015508319A5 (OSRAM) |